At the end of 2024, Neuren Pharmaceuticals Limited announced the suspension of its Phase II open-label study of the safety, tolerability, and pharmacokinetics of oral NNZ-2591 in Prader-Willi syndrome (PWS-001) due to a revised development strategy.
1 Discontinued Drug: NNZ-2591 for treatment of Prader-Willi Syndrome
1 Discontinued Research Program
